# US 2024/0002791 A1 · Thymic constructs and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002791 A1
- Document ID: US20240002791A1
- Status: Published application
- Kind: A1
- Application number: 18/039,849
- Filed: 2021-12-08
- Published: 2024-01-04
- Earliest claimed: 2020-12-10
- Assignees: The Francis Crick Institute Limited
- Applicants: The Francis Crick Institute Limited
- Inventors: Paola BONFANTI
- Web page: https://patentgrep.com/patent/US20240002791A1

## CPC

- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- C12N 5/0634: {Cells from the blood or the immune system}
- A61L 27/3687: {characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents}
- A61L 27/3804: {characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells}
- A61L 27/3813: {Epithelial cells, e.g. keratinocytes, urothelial cells}
- A61L 27/3895: {using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions}
- A61L 2430/40: Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a method of producing a thymic construct suitable for implantation into a subject, the method comprising the steps of: (i) providing an acellular scaffold; (ii) seeding the acellular scaffold with thymic epithelial cells having mesenchymal properties; and (iii) culturing the seeded scaffold to produce said construct. The thymic epithelial cells are preferably CD49f+ and may also be VIM+, TE-7+ and/or CD90+. The invention further provides pharmaceutical compositions, uses and therapies using thymic epithelial cells having mesenchymal properties.

## Claims

### Claim 1

A method of producing a thymic construct suitable for implantation into a subject, the method comprising the steps of:
(i) providing an acellular scaffold;
(ii) seeding the acellular scaffold with thymic epithelial cells having mesenchymal properties; and
(iii) culturing the seeded scaffold to produce said construct.

### Claim 2 (depends on 1)

The method as claimed in claim 1 wherein step (ii) comprises seeding the acellular scaffold with both the thymic epithelial cells (TEC) and thymic interstitial cells (TIC).

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The method as claimed in claim 2 wherein the TEC and TIC are seeded in a ratio of between 3:1 TEC:TIC to 10:1 TEC:TIC, preferably between 4:1 to 8:1 and most preferably around 5:1.

### Claim 5 (depends on 1)

The method as claimed claim 1 wherein the thymic epithelial cells are CD49f+ and preferably also at least one of the group consisting of VIM+ and TE 7+.

### Claim 6 (depends on 5)

The method as claimed in claim 5, wherein the thymic epithelial cells are CD49f+ and CD90+.

### Claim 7 (depends on 1)

The method as claimed in claim 1 wherein the acellular scaffold is produced by decellularizing whole thymus or a part or lobe thereof, wherein the thymus, part or lobe is optionally decellularized by perfusion with a least one decellularization medium selected from the group of a detergent, a protease and a nuclease.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method as claimed in claim 1 wherein step (iii) comprises injecting or perfusing the thymic epithelial cells into and/or onto the scaffold.

### Claim 10

A pharmaceutical composition comprising thymic epithelial cells having mesenchymal properties for regeneration of thymus.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10 comprising thymic epithelial cells having mesenchymal properties for the treatment of thymus, immune or autoimmune disorders.

### Claim 12

A pharmaceutical composition comprising isolated thymic epithelial cells having mesenchymal properties, and a pharmaceutically acceptable carrier, and optionally further comprising isolated thymic interstitial cells.

### Claim 13

(canceled)

### Claim 14 (depends on 12)

The pharmaceutical composition as claimed in claim 12 wherein the thymic epithelial cells comprise medullary thymic epithelial cells (mTEC), cortical thymic epithelial cells (cTEC), or preferably a combination of mTEC and cTEC.

### Claim 15 (depends on 12)

The pharmaceutical composition as claimed in claim 12 wherein the TEC and TIC are seeded in a ratio of between 3:1 TEC:TIC to TEC:TIC, preferably between 4:1 to 8:1 and most preferably around 5:1.

### Claim 16 (depends on 12)

The pharmaceutical composition as claimed in claim 12 wherein the thymic epithelial cells are CD49f+ and preferably also at least one of the group consisting of VIM+, TE-7+ and CD90+.

### Claim 17 (depends on 16)

The pharmaceutical composition as claimed in claim 16, wherein the thymic epithelial cells are CD49f+ and CD90+.

### Claim 18 (depends on 1)

The thymic construct obtained or obtainable by the method of claim 1.

### Claim 19 (depends on 18)

The thymic construct as claimed in claim 18 for use in therapy.

### Claim 20 (depends on 19)

The method of organ transplantation, the method comprising surgically implanting a thymic construct of claim 19 into a patient.

### Claim 21 (depends on 1)

The method as claimed in claim 1, wherein the thymic epithelial cells are substantially all CD90+.

### Claim 22 (depends on 21)

The method as claimed in claim 21, wherein the CD90+ thymic epithelial cells also express VIM and optionally TE-7.

### Claim 23 (depends on 1)

The method as claimed in claim 1 wherein the thymic epithelial cells comprise medullary thymic epithelial cells (mTEC), cortical thymic epithelial cells (cTEC), or preferably a combination of mTEC and cTEC.
